Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	InhaleRx Limited	
ABN	90 611 845 820	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sean Williams
Date of last notice	3 December 2021

#### Part 1 - Change of director's relevant interests in securities

 $In the \ case \ of \ a \ trust, this \ includes \ interests \ in \ the \ trust \ made \ available \ by \ the \ responsible \ entity \ of \ the \ trust$ 

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	TG Advisory Pty Ltd <williams a="" c="" family="" glenair="">  Mr Williams is a director of TG Advisory Pty Ltd and a beneficiary of the Williams Glenair Family A/C</williams>	
Date of change	28 November 2022	
No. of securities held prior to change	200,000 fully paid ordinary shares	
Class	Unlisted Options exercisable at \$0.20 per option and expiring 14/12/2026	
Number acquired	2,000,000	
Number disposed	Nil	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Nil	

<sup>+</sup> See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

No. of securities held after change	200,000 fully paid ordinary shares  Unlisted Options exercisable at \$0.20 per option and expiring 14/12/2026	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Issue of unlisted options under the InhaleRx Limited Incentive Entitlements Plan pursuant to Resolution 4 of the Annual General Meeting held on 31 May 2022.	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)	
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

## Part 3 – \*Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

01/01/2011 Appendix 3Y Page 3

<sup>+</sup> See chapter 19 for defined terms.